Tolerance Bio jumps into phase 2 with $260M deal for thymus-targeting fusion protein

Tolerance Bio has vaulted into the clinic by agreeing to pay NeoImmuneTech up to $260 million for rights to a fusion protein in certain thymus-related indications in the Americas and Europe.